Disc Medicine Inc. (IRON)
NASDAQ: IRON
· Real-Time Price · USD
49.68
0.26 (0.53%)
At close: May 01, 2025, 3:59 PM
49.68
0.00%
After-hours: May 01, 2025, 04:27 PM EDT
Company Description
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis.
The company is based in Watertown, Massachusetts.
Disc Medicine Inc.

Country | United States |
IPO Date | Aug 12, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 84 |
CEO | Dr. John D. Quisel Esq., J.D., Ph.D. |
Contact Details
Address: 321 Arsenal Street Watertown, Massachusetts United States | |
Website | https://www.discmedicine.com |
Stock Details
Ticker Symbol | IRON |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001901203 |
CUSIP Number | |
ISIN Number | US2546041011 |
Employer ID | 00-0000000 |
SIC Code | 6770 |
Key Executives
Name | Position |
---|---|
Dr. John D. Quisel Esq., J.D., Ph.D. | Chief Executive Officer, President & Director |
Dr. Rahul Khara J.D., Pharm.D. | Chief Legal Officer & Secretary |
Dr. Brian MacDonald ChB, MB, Ph.D. | Founder & Chair of Scientific Advisory Board |
Dr. Rahul Rajan Kaushik Ph.D. | Chief Technical Officer |
Dr. William Jacob Savage M.D., Ph.D. | Chief Medical Officer |
Hua Yang Ph.D. | Senior Vice President & Head of Early Development and Clinical Pharmacology |
Jonathan Yu M.B.A. | Chief Opearating Officer |
Pamela Stephenson M.P.H. | Chief Commercial Officer |
Sonia Razzetti Ph.D. | Senior Vice President of Quality |
Srikanth Venkatraman Ph.D. | Senior Vice President & Head of Chemistry |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 14, 2025 | S-4/A | [Amend] Filing |
Apr 07, 2025 | S-4/A | [Amend] Filing |
Mar 18, 2025 | S-4/A | [Amend] Filing |
Feb 25, 2025 | 4 | Filing |
Feb 25, 2025 | 3 | Filing |
Feb 21, 2025 | 10-K | Annual Report |
Jan 31, 2025 | SCHEDULE 13G | Filing |
Jan 28, 2025 | S-4/A | [Amend] Filing |
Dec 23, 2024 | 8-K | Current Report |
Dec 19, 2024 | 425 | Filing |